MONTREAL, April 28 2022 – CQDM is proud to announce the launch of a $5,254,895 project exploring new class of drugs to treat eye pain and blindness. The ministère de l’Économie et de l’Innovation (MEI) will provide $1,268,682 to the project as part of CQDM’s SynergiQC program which, combined with support from public institutions (Mitacs…
Montreal, Quebec, March 10th, 2022 – CQDM is proud to announce the funding of a project in collaboration with the Centre de recherche de l’Hôpital du Sacré-Cœur de Montréal (CIUSSS NIM), NanoGene Therapeutics, the Hôpital du Sacré-Cœur de Montréal Foundation and the Chaire de recherche en orthopédie de l’Université de Montréal. The funding, totalling $333,334,…
Montréal – Québec – March 1st, 2022 – CQDM Is proud to partner with BIOTECanada to present the next Bio+ech Connec+ event taking place on Wednesday, March 16th and featuring Merck. Bio+ech Connec+, is a unique forum for early-stage Canadian biotech companies to connect directly with the business development and investment leaders of multinational pharma/biotech companies. This virtual…
Montreal, Quebec, January 12, 2022 – CQDM is proud to announce the awarding of a grant in collaboration with McGill University, Neurasic Therapeutics, McGill University’s Healthy Brain, Healthy Life (HBHL) initiative and the Louise and Alan Edwards Foundation. This collaborative research project led by Professor Philippe Séguéla, a world-renowned neuroscientist and pioneer in the identification…
Montreal – December 14, 2021 – CQDM is delighted with Monday’s announcement by Pierre Fitzgibbon, Minister of the Economy and Innovation and Minister responsible for Regional Economic Development, at the Board of Trade of Metropolitan Montreal’s Strategic Forum on the Pharmaceutical Industry. Through the FACS, the Quebec government will provide $35 million in funding for…
MONTREAL, November 30, 2021 – During this Lung Cancer Awareness Month, CQDM is proud to announce that it will co-fund a project driven by Dr Philippe Joubert and Pr. Yohan Bossé at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Québec-Université Laval – IUCPQ-UL) targeting a program of early-stage detection…
Montreal – October 7, 2021 – CQDM, the Canadian Cancer Society (CCS), the Cole Foundation (CF) and Oncopole – Pôle cancer du FRQS launch a first call for proposals to support collaborative R&D projects focusing on pediatric and young adult cancers, in particular leukemia and lymphoma. This new research funding, worth up to $5M, builds…
CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies, to support the development of innovative therapies for acute liver failure Montréal – Québec – July 7 – CQDM is proud to announce an investment of $260,100 in Morphocell Technologies, a Montréal- based early-stage regenerative medicine company focused on the development of stem cell-derived engineered liver…
Montreal – June 30th 2021 – CQDM is proud to invest in Giiant Pharma’s seed financing round, joining co-leads Amplitude Ventures and Genesys Capital, along with Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, AQC Capital, Anges Québec, and other angel investor. This financing will enable Giiant Pharma to become a leader in…
CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University to develop new treatments for Amyotrophic Lateral Sclerosis (ALS) MONTREAL, June 21, 2021 – On this Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, CQDM is proud to announce a new $1.7M international collaboration between McGill University, Raya Therapeutic (Montreal – Quebec)…